Objective To compare the medicated urethral system for erection (MUSE) with
standard intracavernosal prostaglandin E1 (PGE1) in the treatment of erect
ile dysfunction.
Patients and methods Sixty consecutive men with organic erectile dysfunctio
n were prospectively randomized to receive either 20 mu g of intracavernosa
l PGE1 (group 1, 30 patients) or 1 mg MUSE (group 2, 30 patients). Response
to the drugs was recorded in the outpatient clinic and all patients contin
ued a home-treatment programme for 3 months. After each home administration
, patients recorded the grade of erection in diaries, whether or not sexual
intercourse occurred and ally adverse reactions to the drugs. Comfort and
ease of administration were also recorded.
Results The characteristics of the patients of both groups were similar; 10
patients in group 1 and 25 in group 2 completed the 3-month treatment prog
ramme, i.e. a withdrawal rate of 67% and 17% for groups 1 and 2, respective
ly (P<0.05). During outpatient dosing, 27 (90%) patients in group 1 and 18
(60%) patients in group 2 achieved a good erection (P<0.05). intercourse du
ring the 3 months of home treatment was reported at least once in 26 (87%)
patients in group 1, compared with 16 (53%) patients in group 2 (P<0.05). A
fter 3 months of home treatment, patients had administered a total of 242 d
oses of intracavernosal PGE1 and 360 doses of MUSE; intercourse was reporte
d after 206 (85%) and 198 (55%) administrations of PGE1 and MUSE, respectiv
ely (P<0.05). The most common adverse reaction was urogenital pain, reporte
d by 14 (47%) patients in group 1 and two (7%) patients in group 2 (P<0.05)
. Home treatment was assessed as easy by 12 (40%) patients in group 1 and 2
7 (90%) in group 2 (P<0.05).
Conclusion Although MUSE is less effective than intracavernosal PGE1. it is
more attractive and accepted well by most patients as an easy method of tr
eatment with minimal or no discomfort.